 Antidepressive Agents, Second-Generation
"Antidepressive Agents, Second-Generation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
| Descriptor ID |
D018687
|
| MeSH Number(s) |
D27.505.954.427.700.122.050
|
| Concept/Terms |
Antidepressive Agents, Second-Generation- Antidepressive Agents, Second-Generation
- Antidepressive Agents, Second Generation
- Second-Generation Antidepressive Agents
- Agents, Second-Generation Antidepressive
- Second Generation Antidepressive Agents
- Atypical Antidepressants
- Antidepressants, Atypical
- Antidepressive Drugs, Second-Generation
- Antidepressive Drugs, Second Generation
- Drugs, Second-Generation Antidepressive
- Second-Generation Antidepressive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents, Second-Generation".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents, Second-Generation".
This graph shows the total number of publications written about "Antidepressive Agents, Second-Generation" by people in this website by year, and whether "Antidepressive Agents, Second-Generation" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 | | 1997 | 1 | 0 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 2 | 0 | 2 | | 2001 | 1 | 0 | 1 | | 2002 | 4 | 1 | 5 | | 2003 | 3 | 0 | 3 | | 2005 | 2 | 0 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 3 | 0 | 3 | | 2008 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antidepressive Agents, Second-Generation" by people in Profiles.
-
Graves SM, Persons AL, Riddle JL, Napier TC. The atypical antidepressant mirtazapine attenuates expression of morphine-induced place preference and motor sensitization. Brain Res. 2012 Sep 07; 1472:45-53.
-
Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, Friedman ES, Shelton RC, Keller MB, Kocsis JH, Gelenberg A. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
-
Olatunji BO, Feldman G, Smits JA, Christian KM, Zalta AK, Pollack MH, Simon NM. Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depress Anxiety. 2008; 25(2):167-71.
-
Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
-
Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
-
Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007; 24(1):1-14.
-
Anagnostou E, Esposito K, Soorya L, Chaplin W, Wasserman S, Hollander E. Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. J Clin Psychopharmacol. 2006 Aug; 26(4):444-6.
-
Karnik NS, Maldonado JR. Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics. 2005 Nov-Dec; 46(6):565-8.
-
Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
-
Gelenberg AJ, Trivedi MH, Rush AJ, Thase ME, Howland R, Klein DN, Kornstein SG, Dunner DL, Markowitz JC, Hirschfeld RM, Keitner GI, Zajecka J, Kocsis JH, Russell JM, Miller I, Manber R, Arnow B, Rothbaum B, Munsaka M, Banks P, Borian FE, Keller MB. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry. 2003 Oct 15; 54(8):806-17.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|